CLINICAL TRIALS PROFILE FOR NPH ILETIN II
✉ Email this page to a colleague
All Clinical Trials for NPH ILETIN II
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01068860 ↗ | To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | Completed | Novartis | Phase 2 | 2010-02-01 | This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NPH ILETIN II
Condition Name
Clinical Trial Locations for NPH ILETIN II
Trials by Country
Clinical Trial Progress for NPH ILETIN II
Clinical Trial Phase
Clinical Trial Sponsors for NPH ILETIN II
Sponsor Name